Intestinal transplantation
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This issue of Current Opinion in Organ Transplantation focuses on the current state of the clinical intestinal transplantation. Outcomes of intestinal transplantation have continued to improve in recent years. Both patient and graft survivals as well as rejection rates and infectious complications have been improved upon. While most of us in the field have searched for a major break through in immunosuppression that would pave the way for more general application of this transplant, no overwhelming advance has been found. Rather, incremental improvements in pre-operative patient management and selection, operative techniques and their applications, immunosuppressive management, early detection of rejection and control of infections, have each contributed to improved outcomes. Improvements in our understanding of the alloimmune response, the interplay between innate and acquired immune systems of the allograft mucosa, and parallels between transplant immunology in the intestinal allograft and disturbances seen in inflammatory bowel disease, will continue to lead us towards improved management strategies for recipients of these transplants.
In this issue, I am delighted to present several articles highlighting the current state of the art of different aspects of intestinal transplantation. In the first article, Dr. Olivier Goulet from Paris reviews the causes of intestinal failure and management of such children in an integrated program for intestinal failure, home parenteral nutrition and intestinal transplantation. Dr. Goulet is an internationally recognized authority on pediatric intestinal failure and transplantation. Over several years the concept of integrated programs for intestinal failure and transplant management has evolved in a paradigm similar to that used for other solid organ failure and transplant pro-grams. His robust understanding of many aspects of surgical and medical diseases causing intestinal failure make him a superb contributor as seen in his article. The next article by Charlene Compher, Ph.D., from the University of Pennsylvania, focuses on adult intestinal failure, its causes, and current state of the art management. Dr. Compher is a recognized authority in diagnosis and management of parenteral nutrition associated liver disease (PNALD). Having followed patients treated since the inception of home parenteral nutrition, Charlene has a unique historical perspective which contributes to her understanding of adult intestinal failure and transplantation. Risk factors for failure among adults treated with long-term parenteral nutrition are expertly reviewed in this article.
Dr. Andreas Tzakis is Chief of Transplantation Services at the University of Miami School of Medicine. He is recognized as a leading authority and contributor of new surgical techniques, specifically relating to intestinal and multivisceral transplantation. While center specific preferences exist related to choices in surgical technique for different patient populations and disease entities, Dr. Tzakis has a robust understanding of the advantages of each choice in the intestinal transplant surgeon's armamentarium.
Clinical immunosuppression for intestinal transplant recipients is then reviewed by Dr. Douglas Farmer, Director Intestinal Transplantation at UCLA. Dr. Farmer has contributed significantly to the evolution of current immunosuppression and infection prophylaxis in intestinal transplantation. Innovations in immunosuppression for intestinal transplantation have paralleled the development of new agents in solid organ transplantation. These have included unmodified donor bone marrow transfusion, allograft irradiation, the use of Campath, Sirolimus, Interleukin-2 antibodies and other approaches. While none has emerged as overwhelmingly more efficacious than others, each has contributed to the current decreasing rates of acute rejection and improved graft survival rates seen in clinical intestinal transplantation. Dr. Farmer reviews the published experience to date with these innovations from the last several years.
Dr. Stuart Kaufman is Medical Director of the Intestinal Transplant Program at Georgetown University and Chil-dren's National Medical Center in Washington, D.C. Dr. Kaufman reviews the medical management of intestinal transplant recipients and their potential complications after transplantation. As we refine our ability to clinically manage post-transplant patients, diagnose infectious complications early, and more accurately treat atypical instances of rejection, our outcomes continue to improve. As one of only a handful of true authorities in the posttransplant management of children with intestinal transplants, Dr. Kaufman discusses recent advances in the context of his subtle understanding of post-transplant clinical observations. Finally, Dr. Jonathan Fryer from Northwestern University and Dr. Kenneth Newell from Emory University combined efforts as two superb scientists who have contributed greatly to our understanding of immunologic processes occurring in the mucosa of the transplanted intestine. Each one pursuing different avenues in his own lab has defined critical aspects of the alloimmune response. Cell-trafficking, graft versus host disease, atypical cell populations in the transplanted mucosa, the role of microbial flora in the allograft and the unique nature of the immunogenicity of epithelial cells in the small bowel are all discussed in this thorough overview of evolving concepts. Ultimately, their ability to continue to define these processes will lead us to new avenues of manipulation of the alloimmune response unique to intestinal transplantation. Hopefully, by the next issue of Current Opinion in Organ Transplantation, we may look back having applied ideas derived from their novel insights.
Whether an authority on intestinal transplantation or hobbyists new to the field, the reader should take away from this section of current opinion a robust understanding of current management of adult and pediatric patients with intestinal failure, indications for transplantation, various surgical options available, should recognize post-transplant complications, be able to choose among immunosuppressive strategies, and thoughtfully evaluate new avenues of investigation to pursue. Each of these contributors is a recognized authority in this fascinating field, and it has been an honor to interact with all of them and the editors in order to compile this edition of Current Opinion.
Over the last several years as I have delved deeper into the practice of intestinal transplantation, I have increasingly recognized complexities of the immune response in the transplanted allograft that are peculiar to this organ. It is well recognized that the small bowel triggers an alloimmune response more commonly aggressive and se-vere than with other organs. Intestinal transplantation has also been associated with a higher incidence of severe infectious complications. While these may be inextricably linked simply to degree of immunosuppression, other explanations may also prevail.
While lung, skin and gastrointestinal tract are components of the human system that most frequently encounter pathogens from the outside world they also are the organs most fraught with immune failure after transplantation. These organ systems have evolved a complex system of innate immunity to deal with constant interaction with the outside world. Little exploration of alteration of the innate immune system has been undertaken but this consideration is increasing recently.
Alterations on innate immunity are seen in inflammatory bowel disease as well, and inflammatory processes after intestinal transplantation often mimic those seen in inflammatory bowel disease. Mild chronic architectural distortion of the mucosa, depletion of crypt paneth cells and protracted mild diarrheal symptoms may accompany long-term graft survival in intestinal transplant recipients. Likewise, early reports from our group and others are beginning to suggest that management strategies for inflammatory bowel disease are efficacious for such problems.
I believe what is building is a picture of dysregulated mucosal immune response in the transplanted bowel. Thus, while we currently target infiltrating recipient lymphocytes we do nothing to enhance the normal suppressive tone of the transplanted donor immune system. Alterations in innate immunity, coupled with suppression of acquired immunity through T-cell immunosuppression may disturb homeostasis between these two systems of defense. As we further investigate the similarities between inflammatory bowel diseases and the transplanted mucosal response I believe it will increasingly suggest the evolution of new therapies parallel to those for inflammatory bowel disease. Such avenues may yield organ specific immune modulations targeting specific cells in the mucosal surface of the transplanted bowel. Whether through augmentation of defensin production, selective re-population of appropriate microbiota of the bowel, or targeted alteration of the cytokine milieu of the graft, all may represent new avenues for exploitation in intestinal transplant management. I hope the reader enjoys superb contributions of the authors contributing to the section. I also hope they are able to peak the interest of those of you not involved in intestinal transplantation to further your participation in this fascinating and evolving field.
